Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Sarepta (SRPT) downgraded to Underperform at Jefferies by analyst Gena Wang, who said she continues to see a low probability of approval for eteplirsen by the May 26 FDA action date. The analyst said that the FDA officials emphasized that the agency is a science organization while Dr. Woodstock's sympathy to Duchenne muscular dystrophy patients fueled some speculation on potential approval. She believes the "current weak evidence" based on the FDA's analysis could not support the drug's effect. 2. Fiat Chrysler (FCAU) downgraded to Underperform at BofA/Merrill with analyst John Murphy saying the company is making significant progress on its turnaround, but has concerns about its high leverage versus peers. 3. Ford (F) downgraded to Neutral at BofA/Merrill by analyst John Murphy, who said he believes the pace of improvement may slow in the second half of 2016, partly due to the upcoming changeover and launch of the SuperDuty in Q3 and Q4. He sees no obvious near-term catalysts to drive shares meaningfully higher. 4.Molina Healthcare (MOH) downgraded to Underperform at BofA/Merrill saying 2017 guidance appears increasingly unrealistic and with low visibility. The company was also downgraded to Neutral at UBS by analyst A.J. rice, who said the miss in Q1 is a "step back." The analyst believes that the updated 2016 guidance is "not a kitchen sink." 5. Green Bancorp (GNBC) downgraded to Neutral at SunTrust after the company announced its decision to not sell itself when it reaches $5B in assets, as it previously stated it would do. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage,
click here.